Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Olezarsen in Severe Hypertriglyceridemia
2022-501999-26-00Phase 3Authorised
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 33
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in hypertriglyceridemia, sponsored by Ionis Pharmaceuticals. Primary endpoints: Key safety laboratory changes and clinical events over long-term olezarsen exposure, Overall adverse events and 1 more. Planned start Jul 2023; status: authorised.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2022-501999-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501999-26-00.